<DOC>
	<DOCNO>NCT01069523</DOCNO>
	<brief_summary>All subject study child ( age 6-12 ) Attention Deficit Hyperactivity Disorder ( ADHD ) . After baseline assessment confirm presence ADHD , child Event relate potential ( ERP ) ( type electroencephalogram [ EEG ] ) study . After baseline EEG , child randomize either placebo GXR 4-week , parallel group trial . During trial , dose flexibly adjust accord patient response presence side effect . The dosage range 1-4 mg. At end four week trial , follow ERP study obtain .</brief_summary>
	<brief_title>Electrophysiological Effects Guanfacine Extended Release Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>All subject study child ( age 6-12 ) Attention Deficit Hyperactivity Disorder ( ADHD ) . After baseline assessment confirm presence ADHD , child Event relate potential ( ERP ) ( type electroencephalogram [ EEG ] ) study . After baseline EEG , child randomize either placebo GXR 4-week , parallel group trial . During trial , dose flexibly adjust accord patient response presence side effect . The dosage range 1-4 mg. At end four week trial , follow ERP study obtain . Our hypothesis : A ) GXR superior placebo reduce symptom ADHD measure standardized clinical diagnostic tool week 3 treatment . B ) Compared placebo pretreatment measure , GXR week 4 treatment increase amplitude right frontal N200 frontal-central P300 , change correlate clinical response .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Children age 612 year Meet criterion Attention Deficit Hyperactivity Disorder Do meet criterion Major Depression , Bipolar , Autism Talking psychotropic medication condition ADHD History epilepsy , severe head injury loss consciousness History Intolerance guanfacine</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Attention Deficit Disorder Hyperactivity</keyword>
	<keyword>Guanfacine</keyword>
	<keyword>Event Related Potentials</keyword>
</DOC>